The minimal residual disease (MRD) testing market — molecular diagnostic assays that detect trace, sub-clinical cancer cells or circulating tumor DNA remaining after treatment, often months before relapse would be visible on imaging — has moved decisively from research laboratories into routine oncology care, with the Minimal Residual Disease Mrd Testing Market sized in the range of roughly USD 2-5 billion currently and projected by multiple analyst firms to reach between USD 5.2 billion and USD 8 billion by the mid-2030s, growing at compound annual growth rates around 11-12%. Hematologic malignancies remain the clinical anchor of the market — commanding an estimated 68% share of MRD testing volume — thanks to well-established clinical guidelines, validated testing methods, and regulatory approvals such as Adaptive Biotechnologies' FDA-cleared clonoSEQ assay, which tracks residual disease in multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia using next-generation sequencing-based immunosequencing. Solid tumor ctDNA testing is the fastest-growing segment, led by tumor-informed assays like Natera's Signatera, which is gaining clinical traction in colorectal, breast, and bladder cancer management by enabling longitudinal disease tracking and personalized adjuvant therapy decisions. Payer and guideline adoption remains uneven across cancer types — while Medicare and major commercial insurers have expanded reimbursement for several hematologic MRD applications, some payers still classify certain solid-tumor MRD tests as not medically necessary, reflecting a gap between rapidly advancing clinical evidence and more cautious payer policy that continues to shape near-term commercial dynamics. Competitive intensity is rising fast — with Adaptive Biotechnologies, Natera, Guardant Health, Foundation Medicine, Veracyte, and NeoGenomics all actively expanding MRD portfolios, alongside emerging entrants like C2i Genomics pursuing improved sensitivity and AI-enhanced data interpretation — creating a crowded competitive field even though only a small fraction of the dozens of MRD tests on the market currently hold FDA clearance. Technology convergence across next-generation sequencing, digital PCR, and AI-enabled bioinformatics continues to push detection sensitivity into the range needed to catch recurrence at ever-earlier, more clinically actionable stages.

Do you think payer reimbursement policy will catch up to the clinical evidence for solid-tumor ctDNA-based MRD testing in the next few years, or will the current gap between guideline inclusion and payer coverage continue to slow broader adoption outside of hematologic cancers?

FAQ

What is minimal residual disease testing, and which technologies are used to detect it? MRD testing detects very small numbers of cancer cells or tumor-derived genetic material that persist in the body after curative-intent treatment but remain undetectable by conventional imaging or standard diagnostic methods. Core technologies include next-generation sequencing (NGS)-based immunosequencing (used in tests like clonoSEQ for blood cancers), circulating tumor DNA (ctDNA) liquid biopsy assays (used in tumor-informed tests like Signatera and tumor-agnostic tests like Guardant Reveal), multiparameter flow cytometry, and digital and quantitative real-time PCR. These methods allow oncologists to detect potential relapse often months before it would appear on a CT scan or other imaging, enabling earlier treatment intervention.

Which companies and tests are leading the MRD testing market? Adaptive Biotechnologies' clonoSEQ holds FDA clearance for multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia, setting a benchmark for sensitivity and payer coverage in hematologic malignancies. Natera's Signatera is a tumor-informed ctDNA assay widely used in solid tumors including colorectal, breast, and bladder cancer, with reported analytical sensitivity down to roughly 0.01% variant allele frequency. Guardant Health's Guardant Reveal offers a tumor-agnostic, tissue-free approach to ctDNA-based recurrence detection, while Foundation Medicine, Veracyte, NeoGenomics, and Illumina round out a competitive field spanning testing services, genomic profiling, and the underlying sequencing platforms that power MRD assays. Despite dozens of MRD tests available commercially, only a small number currently carry FDA clearance, with most operating as laboratory-developed tests under CLIA regulation.

#MRDTesting #LiquidBiopsy #ctDNA #PrecisionOncology #CancerDiagnostics #MolecularDiagnostics #OncologyInnovation